Dallas, Texas--(Newsfile Corp. - November 14, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition completed its second quarter of ZUNVEYL® commercialization in 3Q25, with launch momentum accelerating across the U.S. long-term care (LTC) channel. Pharmacy orders grew 102% sequentially, supported by record prescription volumes each month and expanding reach into more than 600 nursing homes, while the prescriber base surpassed 500 clinicians. The LTC-focused field team continued reinforce ZUNVEYL's differentiated cognitive and behavioral profile alongside a favorable tolerability signal in real-world use. Management's long-term care call strategy remains central to the launch, with growing evidence of durable adoption and repeat ordering behavior as the brand becomes more embedded in high-volume facilities.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Revenue reached $2.8M in the quarter, including $2.3M of ZUNVEYL net product sales and $0.5M in licensing revenue with strong sequential growth.
• Pro forma cash is about $73.2M after the October equity raise, providing roughly two years of runway at planned operating spend and supported by a $75M ATM facility.
• ZUNVEYL launch momentum is building with more than 500 prescribers, coverage of over 600 nursing homes, and pharmacy orders more than doubling q/q.

Click image above to view full announcement.

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274515